Karus began operations in 2006, the result of a four-year collaboration between the University of Southampton and Cancer Research UK's group at Southampton General Hospital. This multi-disciplinary collaboration has created an extensive portfolio of new therapeutics of which Karus's HDI program is the first to enter development.
To date, Karus has identified development candidates in two therapeutic HDI programs (cancer and psoriasis). The company has also established an HDI program in rheumatoid arthritis and is establishing a platform of therapeutics based on non-HDAC targets with application in cancer and inflammation.
These programs are built upon Karus's medicinal chemistry expertise that has allowed the company to create optimized synthetic HDIs (OS-HDI) with best-in-class potency and optimal drug-like properties. Karus anticipates significant value creating events over the next few years as it moves its first three programs into the clinic for the treatment of cancer, psoriasis and rheumatoid arthritis.
Karus Therapeutics Ltd
John Fairclough Centre
University of Southampton
Highfield
Southampton
Hampshire SO17 1BJ
United Kingdom